| NCT ID | NCT05914649 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Postural Orthostatic Tachycardia Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-19 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-09-19 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).
Eligibility Criteria
Inclusion Criteria: * Patients with diagnosis of Long COVID * SARS-COV2 test positive * Symptoms \> 12 weeks post COVID * Subjective complaint of 'brain fog" or cognitive dysfunction * Patients with diagnosis of Postural Orthostatic Syndrome (POTS) from the Calgary Autonomic Investigation and Management Clinic * Subjective complaint of 'brain fog" or cognitive impairment * Healthy participants * Without POTS or "brain fog" * Age 18 to 60 years * Female and Male * Able to give an informed consent Exclusion Criteria: * Patients with overt causes for POTS (e.g., dehydration, prolonged bed rest) * An inability to safely withdraw from medicine(s) that could make test interpretation difficult and impossible. * Other factors which are in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule. * Unable to give an informed consent.
Contact & Investigator
Satish R Raj, MD MSCI
PRINCIPAL INVESTIGATOR
University of Calgary
Frequently Asked Questions
Who can join the NCT05914649 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Postural Orthostatic Tachycardia Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05914649 currently recruiting?
Yes, NCT05914649 is actively recruiting participants. Contact the research team at autonomic.research@ucalgary.ca for enrollment information.
Where is the NCT05914649 trial being conducted?
This trial is being conducted at Calgary, Canada.
Who is sponsoring the NCT05914649 clinical trial?
NCT05914649 is sponsored by University of Calgary. The principal investigator is Satish R Raj, MD MSCI at University of Calgary. The trial plans to enroll 100 participants.